Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Oral Acetazolamide upto a maximum of 500 mg per day over a period of 8 weeks on patients who are on antipsychotics-- Risperidone/Olanzapine (Which is Treatment As Usual): Oral Acetazola
Sponsors
Anupama Priyamkari
Eligibility
Inclusion criteria
Inclusion criteria: Out patients or in patients diagnosed as schizophrenia, schizoaffective disorder, delusional disorder, psychosis NOS, Non organic psychosis diagnosed using MINI PLUS Both males and females 18 â?? 60 years of age Patients who are treated with Risperidone or Olanzepine Patients who are drug naïve, off medication for atleast 6 months or have been on psychotropic medications for less than 1 month. Without any co-morbid psychiatric illness other than nicotine use
Exclusion criteria
Exclusion criteria: Persons on Acetazolamide for any medical reasons. No known medical conditions in which acetazolamide is contraindicated like hyperchloremic acidosis, hypokalaemia, hyponatremia, adrenal insufficiency, impaired kidney function, hypersensitivity to acetazolamide or other sulphonamides, liver diseases. Pregnancy, lactation Sub normal intelligence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To test the effect of Acetazolamide on weight induced by AntipsychoticsTimepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess in Brief Psychiatric Rating Scale score on patients receiving acetazolamideTimepoint: 8 weeks | — |
Countries
India
Contacts
Public ContactDr Anupama Priyamkari
Yenepoya Medical College
Outcome results
None listed